CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Operating expenses | ||||
| Research and development | $ 3,693,865 | $ 2,565,982 | $ 8,800,813 | $ 4,785,509 |
| Acquired in-process research and development expense | 10,426,257 | |||
| General and administrative | 2,536,179 | 1,655,152 | 4,758,002 | 2,606,804 |
| SEPA financing issuance costs | 559,461 | 559,461 | ||
| Total operating expenses | 6,789,505 | 4,221,134 | 24,544,533 | 7,392,313 |
| Operating loss | (6,789,505) | (4,221,134) | (24,544,533) | (7,392,313) |
| Other income (expense) | ||||
| Change in fair value of warrant liabilities | 229,221 | (161,714) | 103,873 | (9,396,636) |
| Change in fair value of contingent consideration | (217,000) | (101,000) | ||
| PIPE warrant Issuance Costs | (9,534) | (9,534) | ||
| Grant income | 21,316 | 153,685 | 161,151 | 501,529 |
| Currency exchange loss | (36,494) | (47,487) | (57,602) | (74,675) |
| Interest income | 52,168 | 148 | 144,056 | 294 |
| Interest expense | (114) | |||
| Total other income (expense) | 39,677 | (55,368) | 240,944 | (8,969,602) |
| Loss before income tax provision | (6,749,828) | (4,276,502) | (24,303,589) | (16,361,915) |
| Deferred income tax provision | (300) | (231,609) | ||
| Net loss | (6,750,128) | (4,276,502) | (24,535,198) | (16,361,915) |
| Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock | (115,015) | (1,840,240) | ||
| Net loss attributable to common stockholders | (6,865,143) | (4,276,502) | (26,375,438) | (16,361,915) |
| Net loss attributable to common stockholders, diluted | $ (6,865,143) | $ (4,276,502) | $ (26,375,438) | $ (16,361,915) |
| Weighted-average common shares outstanding, Basic (in shares) | 957,191 | 833,653 | 937,191 | 504,252 |
| Weighted-average common shares outstanding, Diluted (in shares) | 957,191 | 833,653 | 937,191 | 504,252 |
| Net loss per share, Basic (in dollars per share) | $ (7.17) | $ (5.13) | $ (28.14) | $ (32.45) |
| Net loss per share, Diluted (in dollars per share) | $ (7.17) | $ (5.13) | $ (28.14) | $ (32.45) |
| X | ||||||||||
- Definition Amount of expense incurred for in-process research and development acquired in a business combination consummated during the period. No definition available.
|
| X | ||||||||||
- Definition Change In Fair Value Of Contingent Consideration. No definition available.
|
| X | ||||||||||
- Definition Amount of financing issuance costs incurred during the period. No definition available.
|
| X | ||||||||||
- Definition Amount of grant income recognized during the period classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of warrant issuance costs incurred in PIPE. No definition available.
|
| X | ||||||||||
- Definition Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Accretion of temporary equity during the period due to cash, stock, and in-kind dividends. This item is an adjustment to net income necessary to derive net income apportioned to common stockholders and is to be distinguished from Temporary Equity, Accretion of Dividends (Temporary Equity, Accretion of Dividends). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|